Laboratorios LASCA: Paraguay’s Export-Grade Pharmaceutical Manufacturer

LASCA and Vicente Scavone & Cía. Are the Same Industrial Story

LASCA is the pharmaceutical brand associated with Vicente Scavone & Cía. S.A.E. REDIEX identifies the legal company and Laboratorios LASCA together in its documentation of the 2023 INVIMA certification. Paraguay’s stock exchange also lists Vicente Scavone & Cía. S.A.E. as an issuer engaged in the industrial manufacture of medicinal, chemical-pharmaceutical and related products.

This legal distinction matters for company analysis. LASCA is the operating pharmaceutical identity visible in medicines and corporate communication, while Vicente Scavone & Cía. S.A.E. is the corporate entity that appears in capital-market and regulatory records.

Econosur does not assign current shareholder percentages because a sufficiently current primary-source ownership table has not been identified. The Scavone name is central to the company’s history and governance, but historical family involvement is not a substitute for a current cap table.

The Industrial Story Starts Before Paraguay Had a Modern Pharma Sector

LASCA traces its origin to March 1935, when Vicente Scavone established Vicente Scavone & Cía. after the development of the Farmacia Alemana business. The company’s first dedicated pharmaceutical manufacturing plant opened in 1957.

The following year, LASCA says it produced Paraguay’s first domestically manufactured antibiotic. Over subsequent decades the company added specialized areas for different pharmaceutical categories and expanded its production infrastructure.

The distinction between 1935 and 1957 is important. The first date marks the company’s origin; the second marks the start of dedicated industrial pharmaceutical production. Treating both as the same event would overstate the length of the manufacturing history.

Biotechnology Is the Information-Gain Layer

LASCA’s biotechnology operation changes the interpretation of the company. Paraguay is often viewed as a small pharmaceutical market with local generic manufacturing and imported high-value medicines. LASCA adds a more technically demanding layer to that picture.

The company describes a biologics facility producing pre-filled syringe products including erythropoietin, enoxaparin and heparin. These are not consumer health products; they require more demanding production controls, sterile processes and regulatory oversight than basic oral solid medicines.

LASCA also states that it established Paraguay’s first biotechnology fractionation capability. Company claims about technical firsts should be treated as corporate reporting unless independently documented, but the physical existence and regulatory inspection of the biologics plant are externally corroborated by REDIEX.

INVIMA Turned Manufacturing Capability Into a Market-Access Asset

In September 2023, REDIEX reported that Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) granted Good Manufacturing Practices certification to Vicente Scavone & Cía. S.A.E. / Laboratorios LASCA.

The certification followed an on-site inspection and specifically covered the biologics plant. REDIEX also documented support for staff preparation and training related to the certification process.

LASCA states that the approval enabled exports of enoxaparin and erythropoietin to Colombia. That is the key commercial implication: manufacturing capacity became more valuable once a foreign regulator accepted the relevant production system.

Exports and Contract Manufacturing Extend LASCA Beyond Paraguay

LASCA describes exports to markets in South America, Central America and Eurasia. The company also offers third-party manufacturing and CDMO-type services, giving it a second route to regional integration beyond the sale of its own brands.

The distinction matters. A Paraguayan laboratory can internationalize in several ways: export its own registered products, manufacture for other pharmaceutical companies, represent foreign brands locally, or combine these models.

LASCA’s publicly identified relationships with companies such as Janssen, Grünenthal, Merck and Omron should be read carefully. The company presents these firms within representation or commercial relationships. Econosur does not infer that LASCA manufactures their products unless a specific manufacturing agreement is separately documented.

Paraguay’s Pharma Industry Is Larger Than the Country’s Size Suggests

LASCA operates inside a national pharmaceutical industry that has expanded materially. A sector study published through the Unión Industrial Paraguaya and CIFARMA reported more than 45,000 direct and indirect jobs, approximately 74% capacity utilization and a roughly 60% increase in national laboratory sales over five years.

Banco Central del Paraguay trade data add a current export measure. Pharmaceutical exports increased from US$74.7 million in 2024 to US$88.9 million in 2025, a rise of 18.9%.

Those figures do not mean Paraguay has become a major global pharmaceutical exporter. They show that medicines have become a meaningful manufactured export category for a small economy whose industrial base is often discussed primarily through maquila, automotive components and food processing.

This makes LASCA relevant to Econosur’s analysis of Paraguay’s industrial expansion model. Pharmaceuticals use a different regulatory framework from automotive maquila, but the underlying economic question is similar: how can a small domestic market become a production location inside larger regional demand systems?

70% by Volume Does Not Mean 70% of the Pharmaceutical Market

One of the easiest Paraguayan pharma statistics to misread is the claim that domestic production covers around 70% of the market. CIFARMA’s explanation is more precise.

According to the industry association, locally produced medicines account for around 70% of medicine units used in Paraguay, but only around 40% of the market in monetary terms. The gap reflects both lower prices for locally produced products and continued import dependence in expensive categories such as oncology and other high-cost therapies.

The distinction is central to LASCA’s market position. Paraguay can be strong in physical pharmaceutical production while still importing a disproportionate share of pharmaceutical value.

Public Procurement Creates Demand — and Working-Capital Risk

Paraguay’s public health system is an important pharmaceutical buyer. That creates scale for domestic manufacturers and distributors, but it also makes state payment performance a material sector risk.

In January 2026, CIFARMA’s president said the Paraguayan state owed the pharmaceutical sector more than US$600 million. Government representatives and industry groups have used different calculations, so Econosur treats the figure as industry-reported rather than a settled audited liability.

The commercial implication is clear even without fixing one definitive debt number. Long payment cycles increase financing requirements for companies supplying medicines and medical inputs to public buyers. Sector representatives have warned that persistent arrears can reduce supplier willingness to participate in tenders.

This is not presented as a LASCA-specific receivable. It is a market-level exposure for companies operating in Paraguay’s pharmaceutical supply system.

The Econosur Reading

LASCA is a useful counterweight to the idea that Mercosur pharmaceutical capability is concentrated only in Brazil and Argentina. Paraguay has a smaller industrial base, but LASCA demonstrates a progression from domestic manufacturing into more specialized production and externally validated regulatory capability.

The company also clarifies what regional integration can look like without a single Mercosur pharmaceutical regulator. LASCA produces in Paraguay, qualifies a specific plant against Colombian GMP requirements, exports selected products and offers third-party manufacturing. Market integration occurs through repeated country-by-country regulatory and commercial steps.

That makes LASCA a concrete company case for Econosur’s Mercosur Pharma Futures analysis. The company supports the possibility of broader regional pharmaceutical production, while the need for separate foreign regulatory qualification illustrates why regulatory fragmentation remains a practical constraint.

Paraguay’s own market structure reinforces the same point. Domestic producers dominate medicine consumption by units, but imports remain much more important by value. Industrial capability has deepened without eliminating external dependence.

Marcus A. Volz

Marcus A. Volz is a market analyst and international B2B consultant specializing in South American markets. His company analysis focuses on ownership, industrial assets, regulatory access, market structure and the commercial systems connecting local production with regional and international demand.